Regenovue Fine Plus Lidocaine (1×1.1ml)

Avoid alcohol for 24h before and 48h after the procedure. Alcohol acts as a vasodilator, which can exacerbate post-injection swelling and increase the visibility of bruising in delicate areas like the under-eyes or perioral region.

Common reactions include temporary redness, mild swelling, and localized purple bruising at the injection sites. These effects are generally transient and resolve within 3 to 5 days. For a smooth recovery, patients should follow our expert aftercare guide. Its soft-viscosity nature is comparable to E.P.T.Q. S100, minimizing the risk of visible lumps in thin skin.

Regenovue Fine Plus acts by physically filling the superficial dermis, smoothing fine lines through mechanical displacement and attracting water molecules for secondary hydration. While it shares some properties with skin boosters, its cross-linked matrix provides superior structural persistence. For long-term skin quality improvement, it can be combined with Jalupro HMW in multi-layered protocols.

Treatment is strictly contraindicated. No clinical safety data exists for cross-linked HA fillers during pregnancy or breastfeeding. Practitioners must always monitor for signs of vascular occlusion and prioritize patient safety by deferring elective injections until the nursing period has concluded.

The formulation contains 24 mg/ml of monophasic cross-linked Sodium Hyaluronate and 0.3% Lidocaine hydrochloride. It is often compared to the soft integration properties of Dermalax Plus. To uphold medical standards, always ensure Liporase (Hyaluronidase) is available in the clinic for immediate use.

Dosage is individualized based on the depth of the lines and the target area. Typically, 0.5 ml to 1.1 ml is sufficient for a full periorbital session or subtle lip hydration. Practitioners should evaluate if 0.5 ml of filler is sufficient for minor refinements before utilizing the full syringe capacity. For superficial work, it integrates similarly to Revolax Fine in the upper dermal layers.